Seres Therapeutics announces three presentations at 2026 ESCMID congress

Seres Therapeutics (MCRB) announced three presentations at the 2026 European Society of Clinical Microbiology and Infectious Diseases, ESCMID, global congress, taking place April 17-21 in Munich, Germany. A poster presentation by Seres highlighted biomarker and clinical pharmacology data from the Company’s Phase 1b study of SER-155, evaluating changes in gastrointestinal microbiome composition following administration in patients undergoing allogeneic hematopoietic cell transplantation. Data showed that administration of SER-155 induced a significant and durable shift in GI microbiome composition relative to placebo, characterized by high SER-155 species relative abundance. In addition, an oral presentation by Dr. Ines Moura of the University of Leeds describes the use of an in vitro colonic model (MiGut) to recapitulate patient-specific microbiome composition and inflammatory responses in inflammatory bowel disease